CRO Sekisui XenoTech adds new test systems to offerings

By Melissa Fassbender contact

- Last updated on GMT

(Image: Sekisui XenoTech)
(Image: Sekisui XenoTech)

Related tags: Cell

Sekisui XenoTech now offers hepatic human lysosomes and rat tritosomes as standard test systems for in vitro drug development.

The rationale behind releasing these products is that there is not a high quality, specific, relevant, easy and ready to use, in vitro test system to monitor stability/catabolism of targeted biotherapeutics like there is for small molecule compounds (i.e. microsomes)​,” Chris Bohl, Ph.D., Global Technical Support Manager for Sekisui XenoTech’s products, told Outsourcing-Pharma.com.

Bohl explained that as target biotherapeutic strategies become more common in development pipelines, there will be an increased need to quickly test the characteristics of candidate molecule/modifications “prior to testing them in more complicated, time consuming, and more costly test systems​.”

Lysosomes are an important in vitro diagnostic tool because they are the most representative test system available, as they are the organelle that is being targeted by designers to be the site of activation by taking advantage of unique characteristics inherent to lysosomes​,” explained Bohl.

Development groups have had to rely on purified recombinant enzymes, cell homogenates, or cell lines engineered to overexpress certain proteins to acquire reagents to test biotherapeutics’ metabolism​,” he added.

However, Bohl explained that while these systems offer “certain favorable characteristics​,” they can’t replicate the environment that compounds will encounter in the native lysosome and they don’t account for inherent differences between primary human tissue and cell lines. 

While the isolated lysosomes that we offer are disrupted and no longer offer structural characteristics of lysosomes, they offer a complete and stoichiometrically correct enrichment of lysosomal contents from human primary tissue​,” said Bohl.

Currently, Bohl said the company is seeing the most demand from researchers that are developing ADCs, RNAi technologies, and immunotherapies.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars